Antirheumatic Agents

Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial
Joy Ardjuna van der Pol, Gülşah Akdemir, Marianne van den Broek, Linda Dirven, Pit J S M Kerstens, Willem F Lems, Iris M Markusse, Tom W J Huizinga, Cornelia F Allaart

RMD Open Apr 2023, 9 (2) e002995; DOI: 10.1136/rmdopen-2023-002995
Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis
Joakim Lindqvist, Johan Askling, Jon Lampa

RMD Open Nov 2023, 9 (4) e003111; DOI: 10.1136/rmdopen-2023-003111
New animal model of chronic gout reproduces pathological features of the disease in humans
Jiwei Wang, Peiqi Hao, Xianrun Sun, Richard Ward, Tao Tang, Xi Chen, Yihong Liu, Guancong Luo, Yang Yang, Cheng Xiang, Su An, Tian-Rui Xu

RMD Open Nov 2023, 9 (4) e003499; DOI: 10.1136/rmdopen-2023-003499
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
Alexandra Ladouceur, Thomas Barnetche, Gael Mouterde, Alice Tison, Samuel Bitoun, Sorilla Prey, Caroline Dutriaux, Emilie Gerard, Anne Pham-Ledard, Marie Beylot-Barry, Maeva Zysman, Rémi Veillon, Charlotte Domblides, Amaury Daste, Marine Gross-Goupil, Baptiste Sionneau, Felix Lefort, Mathieu Larroquette, Christophe Richez, Marie-Elise Truchetet, Thierry Schaeverbeke, Marie Kostine

RMD Open Nov 2023, 9 (4) e003795; DOI: 10.1136/rmdopen-2023-003795
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
Martin Rudwaleit, Michael F Mørup, Brittany Humphries, Noor-E Zannat, Damon Willems, Vanessa Taieb, Annelies Boonen

RMD Open Nov 2023, 9 (4) e003468; DOI: 10.1136/rmdopen-2023-003468
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
Yvette Meissner, Martin Schäfer, Katinka Albrecht, Joern Kekow, Silke Zinke, Hans-Peter Tony, Anja Strangfeld

RMD Open Oct 2023, 9 (4) e003489; DOI: 10.1136/rmdopen-2023-003489
Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
Haoming Yuan, Shaoxin Cui, Lin Yang, Jiehan Cui, Xiaoping Wang, Meng Ding, Lu Jin, Yanru Wang, Fei Chang, Hongtao Jin, Jun Ma, Min Shi, Aijing Liu

RMD Open Oct 2023, 9 (4) e003487; DOI: 10.1136/rmdopen-2023-003487
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Christina Charles-Schoeman, Ernest Choy, Iain B McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R Curtis

RMD Open Nov 2023, 9 (4) e003392; DOI: 10.1136/rmdopen-2023-003392
Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
Vinod Chandran, Vladislav A Malkov, Kaori L Ito, Yihua Liu, Lene Vestergaard, Oh Kyu Yoon, Jinfeng Liu, Mona Trivedi, Angie Hertz, Dafna Gladman

RMD Open Nov 2023, 9 (4) e003550; DOI: 10.1136/rmdopen-2023-003550
High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
Katinka Albrecht, Anne Constanze Regierer, Anja Strangfeld, Ursula Marschall, Johanna Callhoff

RMD Open Mar 2023, 9 (1) e002960; DOI: 10.1136/rmdopen-2022-002960

Main menu

Antirheumatic Agents

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Antirheumatic Agents

Pages